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ABSTRACT
Aims: 5-Fluorouracil (5-FU) is one of the most widely
used anticancer drugs; however, the activity of 5-FU is
determined by the presence of several enzymes that limit
its activation or degradation, and these include dihydro-
pyrimidine dehydrogenase (DPD), orotate phosphoribosyl
transferase (OPRT), thymidylate synthase (TS), thymidine
kinase (TK), thymidine phosphorylase (TP) and deoxyur-
idine triphosphatase (dUTPase). The aim of this study was
to compare the expression levels of these enzymes
between the primary colorectal cancer of patients with
and without distant metastases. Furthermore, there was
a comparison of these expression levels between the
primary tumour and the corresponding metastasis.
Methods: Of 55 patients with colorectal cancer, 20 had
no metastasis and the other 35 had distant metastasis. A
strong expression was classified as positive, while weak
to moderate or no expression was negative by
immunohistochemistry.
Results: Of the six 5-FU-related enzymes, the numbers of
patients with expression of dUTPase (54% versus 15%;
p=0.005), TK (26% versus 0%; p=0.019) and DPD
(17% versus 45%; p=0.033) were significantly different
in those with primary tumours with metastasis compared
with those with non-metastasis, respectively. The altered
expression of OPRT (34.3%), TS (40.0%) and dUTPase
(42.9%) was significantly greater from primary to
metastasis among the 35 patients with metastasis. By
contrast, the expression of OPRT, TS and dUTPase was
decreased in 6, 5 and 7 patients, respectively, in
metastatic sites.
Conclusions: From this comparative study of the six 5-
FU-related enzymes in colorectal cancer, the expression of
dUTPase was most significantly different between primary
tumours and their corresponding metastatic tumour. It is
suggested that dUTPase may be a predictive biomarker
for the metastatic potential of colorectal cancer.
5-Fluorouracil (5-FU) is one of the most widely
used anticancer drugs for the treatment of cancers
of the colon, breast, skin, head and neck, stomach
and liver.
125-FU-based chemotherapeutic regimens
have also become standard treatment for digestive
tract cancers. However, to exert an anticancer
effect, 5-FU must be intracellularly activated to
inhibit thymidylate synthase (TS) activity, or be
incorporated into RNA and/or DNA.
3 Cancer cell
sensitivity to 5-FU is often influenced by the
presence of enzymes affecting anabolism and/or
catabolism, and these enzymes include dihydro-
pyrimidine dehydrogenase (DPD), orotate phos-
phoribosyl transferase (OPRT), thymidine
phosphorylase (TP) uridine phosphorylase (UP)
and thymidine kinase (TK).
34Salonga et al
5 have
previously reported that overexpression of DPD, in
addition to TP and TS, appears to be an important
indicator of poor prognosis in patients with
advanced colorectal cancer treated with 5-FU-
based chemotherapy. Overexpression of deoxyur-
idine triphosphatase nucleotide hydrolase
(dUTPase) is also significantly associated with
poor prognosis in colorectal cancer patients treated
with 5-FU.
6
Among 5-FU-related enzymes, DPD, a rate-
limiting enzyme involved in the degradation of
pyrimidine base and pyrimidine-based antimetabo-
lites, is well known to play a critical role in tumour
responses and the general toxicity of 5-FU.
7 In the
human DPD gene (DPYP), 39 mutations and
polymorphisms have been identified,
89 and
patients with DPD-deficient mutations have been
shown to suffer severe toxicity when treated with
5-FU.
10 11 On the other hand, overexpression of
DPD is associated with the rapid metabolism of
5-FU resulting in its deactivation and weak clinical
response. Kobunai et al
12 have reported that low
sensitivity to 5-FU-based drugs is significantly
correlated with a higher copy number and mRNA
levels of the human DPD gene in 31 human
tumour xenografts, suggesting that DPD is a
potent predictive biomarker for 5-FU-based chemo-
therapy. Except for DPD, however, the role of
other enzymes in clinical responses to 5-FU or
other relevant pyrimidine-based antimetabolites
has not been well established. Identification of
any predictive marker enzyme in 5-FU-related
metabolism that could be associated with malig-
nant progression in cancer may further contribute
to the development of novel anticancer antimeta-
bolites as well as potent 5-FU-related anticancer
drugs.
It is also very important to understand
whether any 5-FU-related enzymes are closely
associated with malignant characteristics, includ-
ing metastasis and invasion of colorectal cancer,
to develop novel and potent antimetabolic antic-
ancer therapeutic drugs. Novel molecular patho-
logical diagnoses can also be developed to
optimise 5-FU- or other antimetabolite-based
chemotherapy against advanced colorectal cancer
by targeting 5-FU-related enzymes specifically
upregulated or downregulated in metastatic
tumours. We will discuss which 5-FU-related
enzyme could predict the metastatic potential of
colorectal cancer.
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Patients and tumour samples
We examined 55 patients with primary colorectal cancer whose
tumours had been completely surgically removed in the
Department of Surgery of Kurume University, between 1999
and 2004 (table 1). Among 55 patients, 20 patients were free of
metastases or recurrences after surgery, and the remaining 35
patients had distant metastases, and these included 18 patients
with lung metastases and 17 patients with liver metastases;
patients with both lung and liver metastases are not included.
The 35 patients were histologically diagnosed as having
metastatic colorectal cancers. The age of the patients with
colorectal cancer ranged from 17 to 83 years (mean 64 years); 30
were men and 25 were women. There were 24 patients with
rectal cancer and 31 patients with colon cancers. The mean
follow-up was 68 months, with a range of 36–84 months.
Immunohistochemical analysis of 5-FU-related enzymes, such
as DPD, OPRT, TS, TK, TP and dUTPase, was performed on 90
tumour tissue samples: 55 primary tumour tissue samples, and 35
metastatic tissue samples of colorectal cancer to distant organs.
Immunohistochemistry
The deepest invasive tissue samples of primary colorectal cancer
and of the corresponding metastatic cancer with non-cancerous
tissue margin were selected for immunohistochemistry. The
expression of 5-FU-related enzymes was determined by using
antibodies supplied by Taiho Pharmaceutical (Saitama, Japan)
using a 4 mm section of paraffin-embedded tissue. Endogenous
peroxidase activity was inhibited by incubating the slides in 3%
H2O2 for 5 min. Antigen retrieval was performed by micro-
waving for 30 min in citrate buffer (pH 6.0) for dUTPase only.
Each slide was incubated overnight with the antibody at 4uC.
For staining detection, the ChemMate Envision method
(DakoCytomation, Glostrup, Denmark) was used with diami-
nobenzidine as the chromogen.
Evaluation of immunohistochemistry
The expression levels of DPD, OPRT, TS, TK and TP were each
classified into two categories as negative or positive. Negative
expression was accepted when a weak to moderate or no
expression in the entire cytoplasm in .10% of cancer cells was
observed. Positive expression was stated when a strong
expression of the entire cytoplasm in .10% of cancer cells
was present. The extent of staining of dUTPase was classified
based on the percentage of cells with strongly stained nuclei:
>50% indicated that a cancer was positive, and (49% or no
expression indicated that it was negative.
Statistical analysis
The association of metastasis status with clinicopathological
characteristics was tested by Fisher’s exact test or Wilcoxon
rank-sum test depending on the type of data. The association of
the expression of 5-FU-related enzymes with primary tumours
was tested by Fisher’s exact test. A p value of ,0.05 was
regarded as significant. The association between expression in
primary tumours and in the corresponding metastasis are
summarised descriptively using 262 tables.
RESULTS
Expression of 5-FU-related enzymes in non-cancerous and
cancerous tissues of colorectal cancers
We first examined whether six 5-FU-related enzymes were
expressed in the non-cancerous epithelium of colorectal cancer
by immunohistochemistry (fig 1). Of these six enzymes, DPD
and TS were expressed in the surface and crypt epithelium.
OPRT was expressed at various levels in the mucosa, and this
enzyme was often highly expressed in the non-cancerous
epithelium adjacent to cancer. TK and TP were not expressed
in the non-cancerous epithelium, and TP was expressed in
stromal components, including monocytes/macrophages. The
expression of dUTPase was specifically observed in the nucleus
of the lower part of the crypt epithelium and often in
intracolorectal lymph nodes.
The expression of each of the six enzymes was classified as
positive or negative in expression intensity assessed by
immunohistochemistry, as shown in fig 1. Among 55 patients
with colorectal cancers, DPD, OPRT, TS, TK, TP and dUTPase
were positively expressed in 27% (15/55), 75% (41/55), 15%
(8/55), 16% (9/55), 5% (3/55) and 40% (22/55) cases of primary
tumours, respectively. The expression levels of OPRT and
dUTPase in the primary tumours of patients with metastasis
were higher relative to the expression of other enzymes (table 2).
Furthermore, TK (p=0.019) and dUTPase (p=0.005) were
expressed in higher levels in patients with metastases, whereas
DPD (p=0.033) was expressed in higher levels in patients
without metastases.
Alteration of expression of 5FU-related enzymes in primary
tumours and corresponding metastases
We next compared the expression levels of 5-FU-related
enzymes between primary tumours and those in corresponding
metastatic tissues resected from the liver and lung, using
immunohistochemistry. Non-cancerous liver and bile duct cells
showed a weak to moderate expression of DPD and TS, but
only a weak expression of OPRT, TK, TP and dUTPase. In
contrast, the non-cancerous bronchial epithelium of the lung
showed a weak to moderate expression of DPD, OPRT and TP,
and almost no expression of TK and dUTPase. The basal cells
of bronchial epithelium in the lung showed a strong expression
of TS.
Representative immunohistochemical data are shown in fig 2,
and they indicate a relatively higher expression of six 5-FU-related
Table 1 Clinicopathological data of colorectal cancers
Characteristic
Patients with no
metastasis
(n=20)
Patients with
metastasis
(n=35) p Value*
Age, median (range) (years) 68 (42–78) 65 (17–83) 0.916
Sex
Male 10 20 0.779
Female 10 15
Location
Rectum 11 13 0.262
Colon 9 22
Differentiation
Good 11 21 0.781
Poor 9 14
Primary tumour stage (T)
T2 1 3 1.00
T3–4 19 32
Adjuvant 5-FU-based
chemotherapy
7 14 0.779
Yes 7 14 0.779
No 13 21
*Calculated by Wilcoxon rank-sum test for age and by Fisher’s exact test for the other
factors.
5-FU, 5-fluorouracil.
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J Clin Pathol 2009;62:364–369. doi:10.1136/jcp.2008.060004 365Figure 1 Expression of 5-fluorouracil-related enzymes in primary colorectal cancers and non-cancerous tissues. In primary tumours, expression
levels were scored as negative (no or weak, or moderate, expression) and positive (strong expression). DPD, dihydropyrimidine dehydrogenase;
dUTPase, deoxyuridine triphosphatase; OPRT, orotate phosphoribosyl transferase; TK, thymidine kinase; TP, thymidine phosphorylase;
TS, thymidylate synthase.
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366 J Clin Pathol 2009;62:364–369. doi:10.1136/jcp.2008.060004Figure 2 Comparison of the expression of 5-fluorouracil (5-FU)-related enzymes in primary colorectal cancers and colorectal metastatic cancers in
five patients. In clinical specimens, the 5-FU-related enzymes showed a higher expression in metastases (lung in three patients and liver in two
patients) than in their primary tumour counterparts. DPD, dihydropyrimidine dehydrogenase; dUTPase, deoxyuridine triphosphatase; OPRT, orotate
phosphoribosyl transferase; TK, thymidine kinase; TP, thymidine phosphorylase; TS, thymidylate synthase.
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patients. Based on these immunohistochemical analyses of 35
clinical specimens, we examined whether the expression of these
enzymes was increased or decreased in metastasis in comparison
with their corresponding primary tumours. Metastatic colorectal
cancers in the liver or lung showed a positive expression for DPD,
OPRT, TS, TK, TP and dUTPase in 9% (3/35), 83% (29/35), 31%
(11/35), 17% (6/35), 6% (2/35) and 57% (20/35) of cases,
respectively (table 3). The expression of dUTPase and OPRT was
found to be relatively higher and was scored more frequently as
positive among the 5FU-related enzymes examined. Correlations
between the expression of 5FU-related enzymes in the primary
tumours and their corresponding metastatic tissues are sum-
marised in 262 tables (table 3). In addition, the rates of positive
expressioninmetastasisamongpatientswithnegativelyexpressed
primary tumours and vice versa are also included. The altered
relative ratios of enzyme expression in metastasis as compared
with primary tumours are also presented. For each enzyme,
expression levels in the metastasis were different relative to the
primarytumours.Inparticular,forTSanddUTPase,14(40%)and
15(42.9%)patientsamong35patientswithmetastasisexperienced
alternation of the enzyme expression levels in metastasis versus
primary tumours. The relative ratios of enzyme expression in the
metastasis were significantly altered in comparison to primary
tumours for OPRT (6/6=100%) and dUTPase (8/16=50%).
DISCUSSION
In our immunohistochemical analysis of six 5-FU-related
enzymes (DPD, OPRT, TS, TK, TP and dUTPase), we compared
the expression levels between the primary colorectal cancer and
the metastasis in the lung or liver. The positive expression rate
of dUTPase was higher in primary tumours with metastasis
than in those without metastasis. We also observed a significant
difference in the positive expression of DPD, TK and dUTPase
between patients with and without metastasis. For each
enzyme, the expression levels were different from those in the
primary tumour and metastasis. The expression of TS and
dUTPase in the metastasis was altered relative to that in the
primary tumour in about 40% of patients. In particular, the
expression of dUTPase in the primary tumour was most
significantly increased in patients with metastatic colorectal
cancers. dUTPase mediates a protective role against eventual
toxicity occurring during DNA replication by reduction of the
dUTP pool. Fleishman et al
13 reported higher dUTPase expres-
sion in colorectal adenocarcinomas with lymph node metastasis
compared with those without metastasis. A relevant study by
Ladner et al
6 also demonstrated that a low nuclear expression
of nuclear dUTPase was associated with a better prognosis
of patients after resection of colorectal cancer. The expression of
dUTPase thus appears to be closely associated with the response
to chemotherapy,
6 an also with the metastatic potential of
Table 2 Comparison of 5-fluorouracil-related enzyme levels in primary tumours between patients with and without metastasis in colorectal cancer*
Enzyme
DPD OPRT TS TK TP dUTPase
Patients with metastasis (%) 17 (6/35) 83 (29/35) 20 (7/35) 26 (9/35) 9 (3/35) 54 (19/35)
Patients with no metastasis (%) 45 (9/20) 60 (12/20) 5 (1/20) 0 (0/20) 0 (0/20) 15 (3/20)
Fisher’s exact test, p value 0.033 0.106 0.234 0.019 0.293 0.005
*Fisher’s exact test was applied to 262 tables defined by marker status (+/2) and metastasis status to test the null hypothesis that the odds ratio was unity.
DPD, dihydropyrimidine dehydrogenase; dUTPase, deoxyuridine triphosphatase; OPRT, orotate phosphoribosyl transferase; TK, thymidine kinase; TP, thymidine phosphorylase; TS,
thymidylate synthase.
Table 3 The expression of 5-fluorouracil-related enzymes between primary tumours and metastatic tumours
Enzyme Primary site
Metastasis site
Altered expression* Negative Positive Total
DPD Negative 27 2 29 Increased: 2/29=6.9%
Positive 5 1 6 (17%) Decreased: 5/6=83.3%
Total 32 3 (9%) 35 Altered: 7/35=20.0%
OPRT Negative 0 6 6 Increased: 6/6=100%
Positive 6 23 29 (83%) Decreased: 6/29=20.7%
Total 6 29 (83%) 35 Altered: 12/35=34.3%
TS Negative 19 9 28 Increased: 9/28=32.1%
Positive 5 2 7 (20%) Decreased: 5/7=71.4%
Total 24 11 (31%) 35 Altered: 14/35=40.0%
TK Negative 23 3 26 Increased: 3/26=11.5%
Positive 6 3 9 (26%) Decreased: 6/9=66.7%
Total 29 6 (17%) 35 Altered: 9/35=25.7%
TP Negative 30 2 32 Increased: 2/32=6.3%
Positive 3 0 3 (9%) Decreased: 3/3=100%
Total 33 2 (6%) 35 Altered: 5/35=14.3%
dUTPase Negative 8 8 16 Increased: 8/16=50.0%
Positive 7 12 19 (54%) Decreased: 7/19=36.8%
Total 15 20 (57%) 35 Altered: 15/35=42.9%
*Altered expression is indicated by determination of each enzymes expression in the primary tumour versus to the metastatic
tumour. The rates of cases with positive or negative expression in the metastasis among cases with negative or positive
expression in the primary tumour are indicated as increased or decreased. The rates of altered expression in the metastasis relative
to that in the primary tumour are given in the row labelled as altered.
DPD, dihydropyrimidine dehydrogenase; dUTPase, deoxyuridine triphosphatase; OPRT, orotate phosphoribosyl transferase; TK,
thymidine kinase; TP, thymidine phosphorylase; TS, thymidylate synthase.
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of the expression of dUTPase in advanced metastatic cancer
may be useful for selecting optimised therapies for patients with
colorectal cancer. Furthermore, no therapeutic drug targeting
dUTPase is used for cancer patients. Further development of
dUTPase-targeting drugs might be useful for colorectal cancer
with metastasis.
The expression of OPRT is known to be closely correlated with
the therapeutic efficacy of a 5-FU-based drug in gastric cancer
14
and colorectal cancer.
15 OPRT was positive at the metastatic site
from the primary lesion in which OPRT was negative in six
patients(table3);however,theexpression of OPRT wasrelatively
higher in primary tumours in patients with (83%) and without
(60%) metastasis (table 2). Although OPRT is a key enzyme that
might be responsible for the therapeutic efficacy of 5-FU-based
chemotherapy, it seems less likely that OPRT predicts the
metastatic potential of colorectal cancer.
In conclusion, of 5-FU-related enzymes, primary tumours
showed a significantly higher expression of dUTPase in patients
with metastasis when compared with dUTPase expression in
patients without metastasis. The expression of dUTPase was also
increased in metastatic sites of eight of 16 patients with negative
expression in their primary sites. The expression of dUTPase may
thus predict the metastatic potential of colorectal cancer.
Competing interests: None.
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Take-home messages
c The present study shows, for what is believed to be the first
time, that expression of deoxyuridine triphosphatase
(dTUPase) was augmented in metastasis as compared with
the primary tumour in colon.
c Primary colorectal cancer showed a significantly higher
expression of dUTPase in patients with metastasis when
compared with dUTPase expression in patients without
metastasis.
c The expression of dUTPase may thus predict the metastatic
potential of colorectal cancer.
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